Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering
The global cell and gene therapy (CGT) supply chain software market is projected to grow from $274 million in 2024 to $1,329 million by 2035, representing a CAGR of 15.2%, during the forecast period 2024-2035.
This research study consists of industry trends, detailed cell and gene therapy supply chain software market analysis, funding and investment trends, partnerships and collaborations analysis, platform utilization trends, stakeholder needs analysis and market impact analysis. The report includes cell and gene therapy supply chain software market forecast and opportunity analysis.
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the software developers in the cell and gene therapy supply chain software market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period 2024-2035.
Advanced therapies, including cell and gene therapy products, have revolutionized healthcare practices. The introduction of such therapeutic options has led to a paradigm shift in the development, production, and consumption of modern medicine. Moreover, such therapies have enabled healthcare providers to treat several rare clinical conditions. In the last few decades, more than 30 such therapeutic modalities have been approved; recent approvals include ELEVIDYS (2023), Adstiladrin (2022), Breyanzi (2022), CARVYKTI (2022), Abecma (2021), AllocordT (2019), LUXTURNAT (2017) and Yescarta (2017).
Further, according to a report published by Novotech, it was anticipated that more than 12 novel cell and gene therapies would be approved by the end of 2023, highlighting lucrative opportunities for stakeholders in this market. Moreover, post-2018, over 40% of the clinical trials registered for the treatment of rare diseases involved the evaluation of novel cell and gene therapy products. It is worth highlighting that, based on an assessment of the current pipeline of cell and gene therapy and the historical clinical success of such products, it is assumed that around 10-20 advanced therapies would get approved by the United States Food and Drug Administration, each year, till 2025. Owing to the increase in the number of approved therapies, the demand for novel software solutions to manage the supply chain is also expected to rise, providing subsequent growth opportunities for cell and gene therapy software providers.
It is important to note that the commercial success of cell and gene therapy products depends not only on their ability to provide the desired therapeutic benefits but also on developers' capacity to efficiently meet all supply chain needs. The cell and gene therapy supply chain is relatively more complex compared to the conventional pharmaceutical supply chain owing to the temperature sensitivity and uniqueness of such products. As a result, there are a number of risks in terms of process inconsistency, including possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital loss, and delivery / tracking-related issues, which needs to be taken care by therapy developers.
This has generated a need for bespoke software solutions, which can be integrated into existing processes and enable the drug developers to oversee and manage the various aspects of the cell and gene therapy supply chain at each step. Over the years, several innovative software solutions, offering supply chain orchestration and needle-to-needle traceability, have been developed. The market has also witnessed an increase in the number of partnerships inked for the advancement of such software solutions. Further, given the growing demand for cost-effective personalized medicinal products, and the cost saving potential of implementing such software solutions, the cell and gene therapy supply chain software market is poised to grow significantly in the foreseen future.
Competitive Landscape of Software Solutions in the Cell and Gene Therapy Supply Chain Software Market
The current market landscape features the presence of close to 175 supply chain software solutions, to manage a variety of steps in the cell and gene therapy development; these software solutions include EMS, LIMS, IMS, COP, QMS, LMS and PMS. Further, these software solutions offer a variety of applications, including regulatory compliance, sample inventory management, workflow management, ordering and scheduling, logistics management, manufacturing management, and patient engagement. Moreover, CGT supply chain software solutions can also be used to maintain the chain of identity and custody throughout the cell therapy cycle in order to provide an end-to-end traceability of the samples.
It is interesting to highlight that close to 100 companies are engaged in providing such software solutions. In order to meet the increasing demand for CGT supply chain software, these companies have undertaken several initiatives, such as entering into strategic collaborations, and expanding their existing capabilities / product portfolios.
North America Holds the Largest Share of the Cell and Gene Therapy Supply Chain Software Market
Presently, close to 55% of the cell and gene therapy supply chain software market opportunity is created by the demand for personalized medicines in North America. This can be attributed to the increasing R&D investments, partnership activity and funding received by various therapy developers for the development of novel cell and gene therapies. Further, the market for these software solutions in Asia-Pacific is expected to grow at a relatively higher CAGR of 20.2%, during the forecast period.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 378 |
| Forecast Period | 2024 - 2035 |
| Estimated Market Value (USD) in 2024 | $274 Million |
| Forecasted Market Value (USD) by 2035 | $1329 Million |
| Compound Annual Growth Rate | 15.2% |
| Regions Covered | Global |
Cell and Gene Therapy Supply Chain Software Market Share Insights
The cell and gene therapy supply chain software market research report presents an in-depth analysis of various software solutions that are involved in managing cell and gene therapies supply chain, across different segments, as defined below:
- Historical Trend: 2018-2023
- Base Year: 2023
- Forecast Period 2024-2035
- Market Size 2024: $274 Million
- Market Size 2035: $1,329 Million
- Growth Rate: CAGR of 15% from 2024 to 2035
- PowerPoint Presentation (Complimentary)
- Customization scope: 15% Free Customization
- Process Component
- Sample Collection and Processing Component
- Manufacturing Component
- Logistics Component
- Patient Identification and Treatment Follow-up Component
- Type of Software
- Enterprise Manufacturing System (EMS)
- Laboratory Information Management System (LIMS)
- Inventory Management System (IMS)
- Cell Orchestration Platform (COP)
- Quality Management System (QMS)
- Logistics Management System (LMS)
- Patient Management System (PMS)
- Mode of Deployment
- On-premises Deployment
- Cloud-based Deployment
- Type of End-user
- Pharmaceutical Companies
- Cell Therapy Labs
- Hospitals / Medical Centers
- Research Institutes / Biobanks
- Scale of Operation
- Clinical Scale
- Commercial Scale
- Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Key Companies Profiled
- Azenta Life Sciences
- Biocair
- BioLife Solutions
- CareDx
- Cryoport
- Lonza
- NMDP BioTherapies
- TraceLink
- TrakCel
- Veeva Systems
- Emerson
- LabVantage Solutions
- Marken
- MasterControl
- QuickSTAT
- Siemens
- Stafa Cellular Therapy
- Steiner
- STEMSOFT Software
- TECHNIDATA
- Thermo Fisher Scientific
- Excel Data Packs (Complimentary):
- Market Landscape Analysis
- Company Competitiveness Analysis
- Funding and Investment Analysis
- Partnership and Collaborations Analysis
- Platform Utilization Cases Analysis
- Market Size an Opportunity Analysis
For more information about this report visit https://www.researchandmarkets.com/r/u0x9fy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
